Organon CEO stands down amid contraceptive sales malpractice probe

Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales malpractice. This follows a probe from the board’s audit committee, which found that Organon was conducting “improper” wholesaler sales practices. This involved encouraging US-based wholesalers to buy more of the company’s contraceptive implant, Nexplanon, than they needed. According to the probe, wrongdoing occurred between 2022 and 2025, with the board identifying misconduct at the ...